Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Bromazepam
- Accession Number
- DB01558
- Type
- Small Molecule
- Groups
- Approved, Illicit, Investigational
- Description
One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines.
- Structure
Structure for DB01558 (Bromazepam)
- Synonyms
- Bromazepamum
- Lectopam
- External IDs
- RO 5-3350
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bromazepam-1.5 - Tab 1.5mg Tablet 1.5 mg Oral Pro Doc Limitee 1997-05-20 2010-07-13 Canada 
Bromazepam-3 - Tab 3mg Tablet 3 mg Oral Pro Doc Limitee 1996-12-04 Not applicable Canada Bromazepam-6 - Tab 6mg Tablet 6 mg Oral Pro Doc Limitee 1996-12-04 Not applicable Canada Lectopam Tab 1.5mg Tablet 1.5 mg Oral Hoffmann La Roche 1986-12-31 2006-07-25 Canada Lectopam Tab 3mg Tablet 3 mg Oral Hoffmann La Roche 1981-12-31 Not applicable Canada Lectopam Tab 6mg Tablet 6 mg Oral Hoffmann La Roche 1981-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Alti-bromazepam 1.5mg Tablets Tablet 1.5 mg Oral Altimed Pharma Inc. 1996-12-31 2005-05-27 Canada Alti-bromazepam 3mg Tablets Tablet 3 mg Oral Altimed Pharma Inc. 1995-12-31 2005-05-27 Canada Alti-bromazepam 6mg Tablets Tablet 6 mg Oral Altimed Pharma Inc. 1996-12-31 2005-05-27 Canada Apo-bromazepam - Tab 1.5mg Tablet 1.5 mg Oral Apotex Corporation 1995-12-31 Not applicable Canada Apo-bromazepam - Tab 3mg Tablet 3 mg Oral Apotex Corporation 1995-12-31 Not applicable Canada Apo-bromazepam - Tab 6mg Tablet 6 mg Oral Apotex Corporation 1995-12-31 Not applicable Canada Gen-bromazepam - Tab 3mg Tablet 3 mg Oral Genpharm Ulc 1995-12-31 2010-08-04 Canada Gen-bromazepam - Tab 6mg Tablet 6 mg Oral Genpharm Ulc 1995-12-31 2010-08-04 Canada Mylan-bromazepam Tablet 1.5 mg Oral Mylan Pharmaceuticals 1995-12-31 2012-10-19 Canada Nu-bromazepam - Tab 1.5mg Tablet 1.5 mg Oral Nu Pharm Inc 1995-12-31 2012-09-04 Canada - International/Other Brands
- Calmepam / Creosedin / Durazanil / Lectopam / Lekotam / Lexaurin / Lexilium / Lexomil / Lexotan / Normoc / Ultramidol
- Categories
- Anti-Anxiety Agents
- Benzazepines
- Benzodiazepine hypnotics and sedatives
- Benzodiazepines and benzodiazepine derivatives
- Benzodiazepinones
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- GABA Agents
- GABA Modulators
- Hypnotics and Sedatives
- Muscle Relaxants
- Muscle Relaxants, Centrally Acting Agents
- Nervous System
- Neurotransmitter Agents
- Psycholeptics
- Psychotropic Drugs
- Tranquilizing Agents
- UNII
- X015L14V0O
- CAS number
- 1812-30-2
- Weight
- Average: 316.153
Monoisotopic: 315.000724604 - Chemical Formula
- C14H10BrN3O
- InChI Key
- VMIYHDSEFNYJSL-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
- IUPAC Name
- 7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
- SMILES
- BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1
Pharmacology
- Indication
For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
- Associated Conditions
- Pharmacodynamics
Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
- Mechanism of action
Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.
- Absorption
Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.
- Volume of distribution
1.56 L/kg
- Protein binding
70%
- Metabolism
Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.
- Route of elimination
Urine (69%), as metabolites
- Half life
10-20 hours
- Clearance
0.82 mL/min/kg.
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Bromazepam is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Bromazepam can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine. Approved Acetyl sulfisoxazole The metabolism of Bromazepam can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Bromazepam is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Bromazepam is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Bromazepam is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Bromazepam. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Bromazepam is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Bromazepam is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Bromazepam is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam. Approved, Illicit, Investigational Ambroxol acefyllinate The therapeutic efficacy of Bromazepam can be decreased when used in combination with Ambroxol acefyllinate. Experimental, Investigational Aminophylline The therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline. Approved Amiodarone The metabolism of Bromazepam can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Bromazepam is combined with Amperozide. Experimental Apalutamide The serum concentration of Bromazepam can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Bromazepam can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam. Approved, Investigational Armodafinil The metabolism of Bromazepam can be decreased when combined with Armodafinil. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Bromazepam is combined with Asenapine. Approved Atazanavir The metabolism of Bromazepam can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Bromazepam can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Bromazepam is combined with Azaperone. Investigational, Vet Approved Azelastine Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azithromycin The metabolism of Bromazepam can be decreased when combined with Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Bromazepam is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Bromazepam is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Bromazepam is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Benzocaine. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Bromazepam is combined with Benzyl alcohol. Approved Boceprevir The metabolism of Bromazepam can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Bromazepam can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Bromazepam can be decreased when it is combined with Bosentan. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved Bromisoval The risk or severity of adverse effects can be increased when Bromazepam is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Bromazepam is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Bromazepam is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Bupivacaine. Approved, Investigational Buprenorphine Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Bromazepam is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Bromazepam is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Bromazepam is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam. Approved, Illicit, Vet Approved Caffeine The metabolism of Bromazepam can be decreased when combined with Caffeine. Approved Canertinib The risk or severity of adverse effects can be increased when Bromazepam is combined with Canertinib. Investigational Carbamazepine The metabolism of Bromazepam can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Bromazepam is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol. Approved Ceritinib The serum concentration of Bromazepam can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Bromazepam is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Bromazepam can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromazepam. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Bromazepam can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The serum concentration of Bromazepam can be increased when it is combined with Cimetidine. Approved, Investigational Cinchocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Bromazepam can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Bromazepam can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Bromazepam can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Bromazepam is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Bromazepam is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Bromazepam is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Bromazepam is combined with Clothiapine. Experimental Clotrimazole The metabolism of Bromazepam can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Bromazepam is combined with Clozapine. Approved Cobicistat The metabolism of Bromazepam can be decreased when combined with Cobicistat. Approved Cocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Bromazepam. Approved, Investigational Crizotinib The metabolism of Bromazepam can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Bromazepam can be decreased when combined with Curcumin. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam. Approved Cyclopropane The risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Bromazepam can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine. Approved Cyproterone acetate The serum concentration of Bromazepam can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Bromazepam is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine. Investigational Darunavir The metabolism of Bromazepam can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Bromazepam can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Bromazepam can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Bromazepam can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Bromazepam is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam. Approved Desipramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Bromazepam is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Bromazepam is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Bromazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Bromazepam is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Bromazepam is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam. Approved, Illicit Dihydroergotamine The metabolism of Bromazepam can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Bromazepam can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Bromazepam is combined with Doramectin. Vet Approved Dosulepin The metabolism of Bromazepam can be decreased when combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin. Approved, Investigational Doxycycline The metabolism of Bromazepam can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Bromazepam is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Illicit Dronedarone The metabolism of Bromazepam can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Bromazepam is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Bromazepam is combined with Dyclonine. Approved Dyphylline The therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline. Approved Ecgonine The risk or severity of adverse effects can be increased when Bromazepam is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Bromazepam is combined with Ecopipam. Investigational Efavirenz The metabolism of Bromazepam can be decreased when combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Bromazepam is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Bromazepam is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Bromazepam can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Bromazepam can be decreased when combined with Eslicarbazepine acetate. Approved Esomeprazole The metabolism of Bromazepam can be decreased when combined with Esomeprazole. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Bromazepam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam. Approved, Investigational Ethanol Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Bromazepam is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Bromazepam is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Bromazepam is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Bromazepam is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Bromazepam is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Bromazepam can be decreased when combined with Etravirine. Approved Ezogabine The risk or severity of adverse effects can be increased when Bromazepam is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Bromazepam is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Bromazepam is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Bromazepam is combined with Fluanisone. Experimental Fluconazole The metabolism of Bromazepam can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Flunitrazepam. Approved, Illicit Fluoxetine The metabolism of Bromazepam can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone propionate. Approved Fluvoxamine The serum concentration of Bromazepam can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Bromazepam can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Bromazepam can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Bromazepam. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Bromazepam is combined with Fospropofol. Approved, Illicit, Investigational Fusidic Acid The serum concentration of Bromazepam can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Bromazepam is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Bromazepam. Approved, Illicit, Investigational Gemfibrozil The metabolism of Bromazepam can be decreased when combined with Gemfibrozil. Approved Gepirone The risk or severity of adverse effects can be increased when Bromazepam is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Bromazepam is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam. Approved Halothane The risk or severity of adverse effects can be increased when Bromazepam is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Bromazepam is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Bromazepam is combined with Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Bromazepam can be decreased when used in combination with Hyaluronidase. Approved, Investigational Hydrocodone Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved Idelalisib The metabolism of Bromazepam can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone. Approved Imatinib The metabolism of Bromazepam can be decreased when combined with Imatinib. Approved Imipramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Bromazepam can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Bromazepam is combined with Indiplon. Investigational Isavuconazole The serum concentration of Bromazepam can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Bromazepam can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid The therapeutic efficacy of Bromazepam can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Bromazepam. Approved, Vet Approved Isoniazid The metabolism of Bromazepam can be decreased when combined with Isoniazid. Approved, Investigational Isradipine The metabolism of Bromazepam can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Bromazepam can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Bromazepam can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Bromazepam can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Bromazepam is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Bromazepam is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Bromazepam is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Bromazepam is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam. Approved Lidocaine The metabolism of Bromazepam can be decreased when combined with Lidocaine. Approved, Vet Approved Lithium cation The risk or severity of adverse effects can be increased when Bromazepam is combined with Lithium. Experimental Lobeglitazone The metabolism of Bromazepam can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Bromazepam is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Bromazepam can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Bromazepam can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Bromazepam is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Bromazepam is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam. Approved Lormetazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Bromazepam can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Bromazepam can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam. Approved Luliconazole The serum concentration of Bromazepam can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Bromazepam can be decreased when it is combined with Lumacaftor. Approved Lurasidone The risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Bromazepam can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Bromazepam is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Bromazepam is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Bromazepam is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Bromazepam is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Bromazepam is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone. Approved Methadone Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Bromazepam is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Bromazepam is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam. Approved Methotrimeprazine Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Bromazepam is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Bromazepam is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Bromazepam is combined with Methylphenobarbital. Approved Metyrosine Bromazepam may increase the sedative activities of Metyrosine. Approved Mexiletine The metabolism of Bromazepam can be decreased when combined with Mexiletine. Approved, Investigational Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam. Approved, Illicit Midostaurin The metabolism of Bromazepam can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Bromazepam can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Bromazepam is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Investigational Mirtazapine Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Bromazepam can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Bromazepam can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Bromazepam can be decreased when combined with Modafinil. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam. Approved Nefazodone The metabolism of Bromazepam can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Bromazepam can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Bromazepam can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Bromazepam can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Bromazepam can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Bromazepam can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Bromazepam is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Bromazepam is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Bromazepam is combined with Olanzapine. Approved, Investigational Olaparib The metabolism of Bromazepam can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine. Approved Omeprazole The metabolism of Bromazepam can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron The risk or severity of adverse effects can be increased when Bromazepam is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Bromazepam is combined with Opium. Approved, Illicit Orphenadrine Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant. Investigational Osimertinib The serum concentration of Bromazepam can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam. Approved Oxprenolol The risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Bromazepam can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam. Approved Pantoprazole The metabolism of Bromazepam can be decreased when combined with Pantoprazole. Approved Paraldehyde Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Bromazepam is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam. Approved, Vet Approved Pentobarbital The metabolism of Bromazepam can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved Perazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Bromazepam is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam. Approved Phenazocine The risk or severity of adverse effects can be increased when Bromazepam is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Bromazepam is combined with Phenibut. Experimental Phenobarbital The metabolism of Bromazepam can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoxyethanol. Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Bromazepam. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam. Approved Pipamperone The risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Bromazepam is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Bromazepam can be decreased when it is combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Bromazepam is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide. Approved Posaconazole The metabolism of Bromazepam can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Bromazepam may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Bromazepam can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Prilocaine. Approved Primidone The metabolism of Bromazepam can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Bromazepam is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Bromazepam is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Bromazepam is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam. Approved Quinisocaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Bromazepam is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon. Approved, Investigational Ranolazine The metabolism of Bromazepam can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam. Approved Remoxipride The risk or severity of adverse effects can be increased when Bromazepam is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam. Approved, Investigational Rifabutin The metabolism of Bromazepam can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Bromazepam can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Bromazepam can be increased when combined with Rifapentine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Bromazepam is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Romifidine. Vet Approved Ropinirole Bromazepam may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Ropivacaine. Approved Rotigotine Bromazepam may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Bromazepam can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Bromazepam. Approved Saquinavir The metabolism of Bromazepam can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Bromazepam can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Bromazepam is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Bromazepam is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Bromazepam can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam. Approved, Vet Approved Sildenafil The metabolism of Bromazepam can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Bromazepam can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Bromazepam can be increased when it is combined with Simeprevir. Approved Sodium oxybate Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Approved St. John's Wort The serum concentration of Bromazepam can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Bromazepam can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam. Approved, Investigational Sulfisoxazole The metabolism of Bromazepam can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Bromazepam is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Bromazepam is combined with Sultopride. Experimental Suvorexant Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Bromazepam is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam. Approved Tasimelteon The risk or severity of adverse effects can be increased when Bromazepam is combined with Tasimelteon. Approved, Investigational Teduglutide The serum concentration of Bromazepam can be increased when it is combined with Teduglutide. Approved Telaprevir The metabolism of Bromazepam can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Bromazepam can be decreased when combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam. Approved, Investigational Tenofovir disoproxil The metabolism of Bromazepam can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Teriflunomide The serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrodotoxin. Investigational Thalidomide Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The therapeutic efficacy of Bromazepam can be decreased when used in combination with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Bromazepam is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Bromazepam is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Bromazepam is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Bromazepam can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab. Approved Tolcapone The risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone. Approved, Withdrawn Topiramate The metabolism of Bromazepam can be decreased when combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Bromazepam is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Bromazepam is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Bromazepam is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Bromazepam is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Bromazepam is combined with Valproic Acid. Approved, Investigational Vemurafenib The serum concentration of Bromazepam can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Bromazepam can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Bromazepam is combined with Veralipride. Experimental Verapamil The metabolism of Bromazepam can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Bromazepam is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Bromazepam is combined with Vinyl ether. Experimental Voriconazole The metabolism of Bromazepam can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Bromazepam is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Bromazepam is combined with Xylazine. Vet Approved Yohimbine The therapeutic efficacy of Bromazepam can be decreased when used in combination with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Bromazepam can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Zolazepam. Vet Approved Zolpidem Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Bromazepam. Approved Zotepine The risk or severity of adverse effects can be increased when Bromazepam is combined with Zotepine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Bromazepam can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451]
- Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [PubMed:14517708]
- van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [PubMed:8846617]
- Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [PubMed:2882883]
- External Links
- Human Metabolome Database
- HMDB0015511
- KEGG Drug
- D01245
- PubChem Compound
- 2441
- PubChem Substance
- 46505694
- ChemSpider
- 2347
- ChEBI
- 31302
- ChEMBL
- CHEMBL277062
- Therapeutic Targets Database
- DAP001035
- PharmGKB
- PA10035
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bromazepam
- ATC Codes
- N05BA08 — Bromazepam
- AHFS Codes
- 28:24.08 — Benzodiazepines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Anxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders 1 3 Unknown Status Prevention Nausea / Vomiting 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- United States Pharmacopeial Convention Inc.
- Dosage forms
Form Route Strength Tablet Oral 1.5 mg Tablet Oral 3 mg Tablet Oral 6 mg - Prices
Unit description Cost Unit Lectopam 6 mg Tablet 0.25USD tablet Lectopam 3 mg Tablet 0.17USD tablet Apo-Bromazepam 6 mg Tablet 0.13USD tablet Gen-Bromazepam 6 mg Tablet 0.13USD tablet Novo-Bromazepam 6 mg Tablet 0.13USD tablet Apo-Bromazepam 3 mg Tablet 0.09USD tablet Gen-Bromazepam 3 mg Tablet 0.09USD tablet Novo-Bromazepam 3 mg Tablet 0.09USD tablet Apo-Bromazepam 1.5 mg Tablet 0.07USD tablet Gen-Bromazepam 1.5 mg Tablet 0.07USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 2.05 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.0399 mg/mL ALOGPS logP 2.09 ALOGPS logP 2.54 ChemAxon logS -3.9 ALOGPS pKa (Strongest Acidic) 12.24 ChemAxon pKa (Strongest Basic) 2.68 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 54.35 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 76.99 m3·mol-1 ChemAxon Polarizability 28.11 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9937 Blood Brain Barrier + 0.9848 Caco-2 permeable + 0.7571 P-glycoprotein substrate Substrate 0.5741 P-glycoprotein inhibitor I Non-inhibitor 0.7251 P-glycoprotein inhibitor II Non-inhibitor 0.924 Renal organic cation transporter Non-inhibitor 0.558 CYP450 2C9 substrate Non-substrate 0.8385 CYP450 2D6 substrate Non-substrate 0.9117 CYP450 3A4 substrate Substrate 0.7117 CYP450 1A2 substrate Inhibitor 0.9381 CYP450 2C9 inhibitor Non-inhibitor 0.6329 CYP450 2D6 inhibitor Non-inhibitor 0.8511 CYP450 2C19 inhibitor Non-inhibitor 0.5719 CYP450 3A4 inhibitor Non-inhibitor 0.7405 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6441 Ames test Non AMES toxic 0.8607 Carcinogenicity Non-carcinogens 0.8704 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.2416 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9974 hERG inhibition (predictor II) Non-inhibitor 0.7977
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzodiazepines
- Sub Class
- 1,4-benzodiazepines
- Direct Parent
- 1,4-benzodiazepines
- Alternative Parents
- Alpha amino acids and derivatives / Pyridines and derivatives / Benzenoids / Aryl bromides / Heteroaromatic compounds / Secondary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds show 5 more
- Substituents
- 1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl bromide / Aryl halide / Pyridine / Benzenoid / Heteroaromatic compound / Carboxamide group / Ketimine / Lactam show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA4
- Uniprot ID
- P48169
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-4
- Molecular Weight
- 61622.645 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA6
- Uniprot ID
- Q16445
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-6
- Molecular Weight
- 51023.69 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB1
- Uniprot ID
- P18505
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-1
- Molecular Weight
- 54234.085 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB2
- Uniprot ID
- P47870
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-2
- Molecular Weight
- 59149.895 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-gated chloride ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB3
- Uniprot ID
- P28472
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-3
- Molecular Weight
- 54115.04 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG1
- Uniprot ID
- Q8N1C3
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-1
- Molecular Weight
- 53594.49 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRG2
- Uniprot ID
- P18507
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-2
- Molecular Weight
- 54161.78 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG3
- Uniprot ID
- Q99928
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-3
- Molecular Weight
- 54288.16 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRD
- Uniprot ID
- O14764
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit delta
- Molecular Weight
- 50707.835 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRE
- Uniprot ID
- P78334
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit epsilon
- Molecular Weight
- 57971.175 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
- Gene Name
- GABRP
- Uniprot ID
- O00591
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit pi
- Molecular Weight
- 50639.735 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
- Gene Name
- GABRR1
- Uniprot ID
- P24046
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-1
- Molecular Weight
- 55882.91 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
- Gene Name
- GABRR2
- Uniprot ID
- P28476
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-2
- Molecular Weight
- 54150.41 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRR3
- Uniprot ID
- A8MPY1
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-3
- Molecular Weight
- 54271.1 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRQ
- Uniprot ID
- Q9UN88
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit theta
- Molecular Weight
- 72020.875 Da
References
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on July 31, 2007 07:10 / Updated on July 13, 2018 01:08